---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Oral appliance therapy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Oral appliance therapy. Topics: VA/DoD guideline: mandibular advancement devices or PAP as first-line options for mild to moderate OSA (weak for); AASM and AADSM guideline: oral appliances for adults intolerant of CPAP or preferring alternate therapy (standard); AASM and AADSM guideline: AHI reduction with oral appliances compared with CPAP, pooled trials, hypopnea scoring rule not stated; ACP guideline: mandibular advancement devices as an alternative to CPAP (weak recommendation, low-quality evidence); 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/oral-appliance-therapy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Oral appliance therapy

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Oral Appliance Therapy

<a id="topic-2.2.2.1.2-1"></a>

### VA/DoD guideline: mandibular advancement devices or PAP as first-line options for mild to moderate OSA (weak for)

> “18. For treatment of mild to moderate obstructive sleep apnea (Event Index <30 per hour), we suggest either mandibular advancement devices or positive airway pressure as first line therapy options. Weak for”
> “The mandibular advancement device (MAD) is the second most studied therapy for OSA, after PAP therapy.”
> “The remaining evidence base reviewed in 2019 and 2025 supported that while MAD therapy may not be as efficacious in reducing the AHI as PAP therapy, the increased usage of MAD, due in part to patient preference and acceptance, can result in more effective treatment.”
> “While the Patient Focus Group confirmed individual preferences varied, most patients exposed to both options preferred MAD over PAP.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### AASM and AADSM guideline: oral appliances for adults intolerant of CPAP or preferring alternate therapy (standard)

> “We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant of CPAP therapy or prefer alternate therapy. (STANDARD)”
> “When oral appliance therapy is prescribed by a sleep physician for an adult patient with obstructive sleep apnea, we suggest that a qualified dentist use a custom, titratable appliance over non-custom oral devices. (GUIDELINE)”
> “We suggest that sleep physicians conduct follow-up sleep testing to improve or confirm treatment efficacy, rather than conduct follow-up without sleep testing, for patients fitted with oral appliances. (GUIDELINE)”
> “The PubMed database was searched from January 1, 2004, through July 31, 2012, and was updated again on February 28, 2013, to capture the latest literature.”

Source: [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/)

<a id="topic-2.2.2.1.2-3"></a>

### AASM and AADSM guideline: AHI reduction with oral appliances compared with CPAP, pooled trials, hypopnea scoring rule not stated

> “In weighted analysis, OAs produced a significant mean reduction in AHI, however the mean reduction in AHI was 6.24 events/h (95% CI: 8.14, 4.34) greater with CPAP than with OA.”
> “For patients with moderate to severe OSA, however, the odds of achieving the target AHI were significantly greater with CPAP than with OAs.”
> “A review of the evidence suggests that adherence rates using OAs are greater than those observed with CPAP. However, no randomized controlled trials have assessed objective OA adherence rate as compared with CPAP.”
> “Although they are not as efficacious as PAP therapy, the benefits of using OAs outweigh risks of not using OAs.”

Source: [Ramar et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481062/)

<a id="topic-2.2.2.1.2-4"></a>

### ACP guideline: mandibular advancement devices as an alternative to CPAP (weak recommendation, low-quality evidence)

> “RECOMMENDATION 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence).”

Source: [Qaseem et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24061345/)

<a id="topic-2.2.2.1.2-5"></a>

### ERS guideline: CPAP over mandibular advancement devices, with equivalence in mild to moderate OSA (conditional recommendation, very low quality of evidence)

> “We systematically searched the following databases from 1 January 1946 until 15 June 2020: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE.”
> “In adult patients with OSA, we suggest that CPAP should be used as compared to MAD (conditional recommendation, very low quality of evidence).”
> “Altogether, those considerations lead the panel to regard CPAP and MAD as equal in patients with mild to moderate OSA. With increasing severity of OSA, comorbidities or odontological concerns, CPAP should be considered in this group of patients.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
